China NMPA Inspection - Anhui Provincial Drug Administration - September 01, 2021

The provided content constitutes an official announcement from the Anhui Provincial Drug Administration Fifth Branch, published on September 1, 2021. This announcement specifically concerns information related to cosmetic production inspections conducted within its jurisdiction during the first half of 2021, spanning from January to June. Operating under the umbrella of China's National Medical Products Administration (NMPA), the Anhui Provincial Drug Administration is a key regional regulatory body responsible for overseeing the quality and safety of cosmetic products. While the document identifies the issuing authority and the timeframe for the inspection activities, it conspicuously lacks specific details regarding any particular inspection event. Consequently, the summary cannot identify a specific company name that was inspected, precise inspection dates for individual audits, any main violations or non-compliance issues discovered, or any mandatory corrective actions stipulated. The information presented is confined to the administrative declaration of cosmetic production inspection information availability for the stated period, rather than a detailed report of findings from a specific inspection.